Malignant lymphoma after diphenylhydantoin (dilantin) therapy
Authors:
Abstract
A history of prolonged diphenylhydantoin (Dilantin) therapy was reported by 8 of 516 patients (1.6%) with Hodgkin's disease or non-Hodgkin's lymphoma, as compared with 3 of 516 patients (0.6%) with other cancers, and 2 of 516 (0.4%) tumor-free individuals. The findings, together with other published data, suggest a small excess risk of malignant lymphomas in patients receiving long-term treatment with this drug. The immunosuppressive effects of chronic diphenylhydantoin therapy may be involved in the pathogenesis of these neoplasms.Keywords
This publication has 24 references indexed in Scilit:
- ARE ANTICONVULSANTS ONCOGENIC?The Lancet, 1974
- RISK OF CANCER IN RENAL-TRANSPLANT RECIPIENTSThe Lancet, 1973
- Immunological Abnormalities and HydantoinsBMJ, 1972
- Role of Immunologic Disturbance in Human Oncogenesis: Some Facts and FanciesBritish Journal of Cancer, 1971
- Vaginal Cancer after Maternal Treatment with Synthetic EstrogensNew England Journal of Medicine, 1971
- Malignant Lymphoma Associated With Hydantoin DrugsArchives of Neurology, 1970
- Pseudolymphoma induced by diphenylhydantoinThe Journal of Pediatrics, 1970
- Hydantoin-Induced Pseudo-PseudolymphomaAnnals of Internal Medicine, 1968
- Diphenylhydantoin-induced hypersensitivity reactionThe Journal of Pediatrics, 1965
- Lymphoma or drug reaction occurring during hydantoin therapy for epilepsyThe American Journal of Medicine, 1962